YTHDF
(YTH) domain-containing family proteins (YTHDF)
(YTH) domain-containing family proteins (YTHDFs) are a class of cytoplasmic m6A-binding proteins characterized by the vertebrate YTH domain, which enables them to regulate RNA fate extensively. The YTH domain serves as the basis for specific recognition of m6A-modified RNA. As the most studied "readers" of m6A, the YTHDF family includes YTHDF1, YTHDF2, and YTHDF3. YTHDF1 promotes RNA translation, while YTHDF2 facilitates RNA decay. YTHDF3 exhibits a dual function that depends on its binding partner. Upon entering the cytoplasm, m6A-modified mRNAs are initially bound by YTHDF3 or a YTHDF3-YTHDF1 complex, followed by recognition by YTHDF2, thereby directing the diverse fates of the targeted mRNA. The YTHDF family plays a significant role in mediating tumor proliferation, metastasis, metabolism, drug resistance, and immunity. Moreover, they possess potential as predictive and therapeutic biomarkers[1].
YTHDF Isoform Specific Products
All Product Categories
-
YTHDF Related Products (12)
-
YTHDF Isoform Comparison
- 1
-
DC-Y13-27
0 ImagesCat. No.: HY-154919Purity: 99.52%DC-Y13-27 is a DC-Y13 derivative and YTHDF2 inhibitor (KD: 37.9 μM). DC-Y13-27 inhibits YTHDF2, restores FOXO3 and TIMP1 protein levels, and reduces MMP1/3/7/9 expression. DC-Y13-27 induces Pyroptosis and increases IL-1β secretion. DC-Y13-27 reduces intervertebral disc degeneration and enhances the response to radiotherapy in colon cancer and melanoma. DC-Y13-27 has antitumor activity against breast cancer.
-
SK-3-91
0 ImagesSK-3-91 is a PROTAC-type multi-kinase degrader that can jointly induce the degradation of the largest number of unique kinases (more than 125 unique kinases). SK-3-91 induces protein (YTHDF2, e.g.) degradation through the ubiquitin biotinylation (E-STUB) pathway. SK-3-91 degrades YTHDF2. SK-3-91 inhibits cell proliferation and induces morphological changes.
-
YTHDF2-IN-1
0 ImagesCat. No.: HY-173008Purity: 99.42%YTHDF2-IN-1 (Compound CK-75) is a selective YTHDF2 inhibitor (Kd = 26.2 μM). YTHDF2-IN-1 binds to a small hydrophobic pocket on the YTH domain of YTHDF2, disrupting the interaction between YTHDF2 and m6A-modified RNA. YTHDF2-IN-1 induces cell cycle arrest and Apoptosis. YTHDF2-IN-1 is applicable to research on chronic myeloid leukemia, colon cancer and choriocarcinoma.
-
SKLB-Y13
0 ImagesCat. No.: HY-176848Purity: 98.44%SKLB-Y13 is a selective YTHDF1 inhibitor with an IC50 of 0.76 μM and a KD of 5.097 μM. SKLB-Y13 binds to the Tyr397 and Trp470 residues in the m6A-binding pocket of YTHDF1, disrupting the interaction between YTHDF1 and m6A-modified mRNA. SKLB-Y13 inhibits cancer cell proliferation and promotes apoptosis. SKLB-Y13 is applicable to breast cancer-related research.
-
YTH-IN-2
0 ImagesCat. No.: HY-181117CAS No.: 86886-76-2
-
PROTAC FTO degrader 1
0 ImagesCat. No.: HY-175885PROTAC FTO degrader 1 is a Fat Mass and Obesity-associated Protein (FTO) PROTAC degrader. PROTAC FTO degrader 1 selectively degrades FTO depending on VHL E3 ligase and ubiquitin-proteasome system. PROTAC FTO degrader 1 can increase m6A modifications on mRNAs associated with ribosome biogenesis and promote their YTHDF2-mediated decay. PROTAC FTO degrader 1 can inhibit cancer cells proliferation and induce apoptosis. PROTAC FTO degrader 1 can be used for the research of cancer, such as acute myeloid leukemia (AML).
- 1
